AXIS HCN ANNOUNCES MANAGEMENT CHANGE

Dr. Gene Emmer appointed VP Business Development

Hoofdoorp, The Netherlands(PRWEB) September 22 2003-- Axis HCN has appointed Dr. Gene Emmer as Vice President Business Development with overall responsibility for leading the companys sales and marketing efforts. Genes initial focus will be to lead the development of the US market for Axis.

Gene brings to Axis more than 14 years of international pharmaceutical sales and marketing experience. He has lead sales and marketing efforts for Hoffmann La Roche in Switzerland, Greece and The UK and Roberts pharmaceuticals in the US (now part of Shire Pharmaceuticals) and was Director of Corporate Communications and Country Manager for Yamanouchi Pharmaceuticals. Gene graduated from UC Berkeley with a bachelors degree in Physiology. He earned his Ph.D. in Physiology from The State University of NY, and his Masters Degree in Management from MIT Sloan School of Management.

Genes broad international background is a tremendous asset to Axis", said Dr. Tony Hall, CEO of Axis HCN. As an American with years of US and European experience and proven expertise in building companies, he is the right person to lead the effort in the US market and continue the rapid growth of Axis."

Axis HCN is a European based CRO established in 2001 with the goal of providing rapid, high quality clinical trial research at a lower cost than US and international CROs. Axis continually seeks ways to drive down the cost of conducting clinical trials without compromising speed and quality. Its high quality standards comply with ICH-GCP guidelines and meet all US and European regulatory requirements.

###